Home / Drugs / Lenvima

Lenvima

Named-patient access overview. Lenvima is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.

Quick orientation

Lenvima (lenvatinib) is an oral multikinase tyrosine kinase inhibitor developed by Eisai that blocks VEGFR1-3, FGFR1-4, PDGFR-alpha, KIT, and RET. The US Food and Drug Administration first approved Lenvima in February 2015 for locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer, with subsequent approvals in advanced renal cell carcinoma (in combination with everolimus or pembrolizumab), unresectable hepatocellular carcinoma, and advanced endometrial carcinoma (in combination with pembrolizumab). It is given as a once-daily oral capsule, with the starting dose set by indication and adjusted for body weight, hepatic function, and tolerability. Lenvima is prescribed and monitored by medical oncology specialists in outpatient cancer-centre settings.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Lenvima

  1. Patient or treating physician submits an intake at the patient portal.
  2. Reserve Meds clinical team verifies appropriateness for the patient and destination country.
  3. Treating physician issues prescription and clinical justification.
  4. Country-specific named-patient documentation is prepared.
  5. Lenvima is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
  6. Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.

Access by country

Reserve Meds publishes a detailed country access guide for Lenvima in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.

Lenvima in Abu DhabiFull deep-dive on regulatory pathway, costs, timing Lenvima in BahrainFull deep-dive on regulatory pathway, costs, timing Lenvima in DubaiFull deep-dive on regulatory pathway, costs, timing Lenvima in IndiaFull deep-dive on regulatory pathway, costs, timing Lenvima in KuwaitFull deep-dive on regulatory pathway, costs, timing Lenvima in OmanFull deep-dive on regulatory pathway, costs, timing Lenvima in QatarFull deep-dive on regulatory pathway, costs, timing Lenvima in Saudi ArabiaFull deep-dive on regulatory pathway, costs, timing Lenvima in UAEFull deep-dive on regulatory pathway, costs, timing

Start a request for Lenvima

Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp

About Lenvima

Oncology (RCC, HCC, DTC, Endometrial)
Manufacturer: Eisai
Modality: oral multikinase tyrosine kinase inhibitor
Generic: lenvatinib

Why Reserve Meds

DSCSA-compliant US sourcing. Physician-led. On-pathway in every destination. Patient-first intake with a named concierge.

Related

Access pathways
Country guidance
Articles & guides

WhatsApp
WhatsApp